8-Oxo-dGTP
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms.
For research use only. We do not sell to patients.
- CAS No.: 139307-94-1
- Formula: C10H16N5O14P3
- Molecular Weight:523.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
8-Oxo-dGTP (100 μM) binds to wild-type hMTH1 with high affinity (Kd=0.08 μM), while the F27A and D119A mutations reduce the binding affinity, and the W117A mutation completely abolishes the binding activity[1].
8-Oxo-dGTP (2-8 mM; 24 h) inhibits the viability of HeLa-shGFP and HeLa-shMTH1 cells in a dose-dependent manner, with the inhibitory effects at concentrations of 6 mM and 8 mM being stronger than that of 50 μg/mL 5-FU[4].
8-Oxo-dGTP (2 mM, 6 mM; 8-24 h) increases the level of 8-oxo-dG in DNA of HeLa-shGFP cells in a dose- and time-dependent manner, and this elevation reaches comparable levels in HeLa cells with MTH1, OGG1 or MUTYH knockdown after 24 h of treatment[4].
8-Oxo-dGTP (6 mM; 24 h) induces S-phase cell cycle arrest in HeLa-shGFP and HeLa-shMTH1 cells, with a more pronounced effect in MTH1-knockdown HeLa cells; treatment with 6 mM 8-oxo-dGTP for 12 h also induces S-phase arrest in double thymidine-synchronized HeLa-shGFP and HeLa-shMTH1 cells[4].
8-Oxo-dGTP (2 mM, 6 mM; 24 h) induces apoptosis in HeLa-shGFP, HeLa-shMTH1, HeLa-shOGG1 and HeLa-shMUTYH cells via an AIF-mediated caspase-independent pathway, which is evidenced by elevated levels of cleaved PARP and nuclear translocation of AIF[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa-shGFP, HeLa-shMTH1
-
Concentration:2 mM, 4 mM, 6 mM, 8 mM
-
Incubation Time:8 h, 16 h, 24 h
-
Result:Inhibited cell viability in a dose-dependent manner in both HeLa-shGFP and HeLa-shMTH1 cells.
Showed higher inhibition rates at 6 mM and 8 mM than the positive control 5-FU (50 μg/mL).
-
Cell Line:HeLa-shGFP, HeLa-shMTH1, HeLa-shOGG1, HeLa-shMUTYH
-
Concentration:2 mM, 6 mM
-
Incubation Time:24 h
-
Result:Induced apoptosis in a dose-dependent manner in HeLa-shGFP and HeLa-shMTH1 cells, with a higher percentage of apoptotic cells in HeLa-shMTH1 cells.
Did not alter the apoptotic response in cells with knockdown of OGG1 or MUTYH.
-
Cell Line:HeLa-shGFP, HeLa-shMTH1, HeLa-shOGG1, HeLa-shMUTYH
-
Concentration:2 mM, 6 mM
-
Incubation Time:24 h
-
Result:Increased cleaved PARP levels in all tested cell lines.
Decreased cytoplasmic AIF levels and increased nuclear AIF levels in all tested cell lines.
Caused no significant changes to classical caspase-dependent pathway proteins (Bcl-2, Bax, Cyto-c, caspase-3).
In Vivo
8-oxo-dGTP (0.5 mg/kg; intravenous injection; once every 3 days; for 32 consecutive days) inhibits the growth of subcutaneous HeLa-shMTH1 xenografts in nude mice[4].
8-oxo-dGTP (0.5-2.5 mg/kg; intravenous injection; once every 5 days; for 112 consecutive days) dose-dependently inhibits spontaneous intestinal adenoma formation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57/6J-ApcMin/Nju mice with Spontaneous intestinal adenoma (male and female; 4 weeks old; fed 60% high-fat diet to induce intestinal polypoid tumors)[4]
-
Dosage:0.5 mg/kg; 2.5 mg/kg
-
Administration:i.v.; every 5 days; 112 days
-
Result:Reduced average intestinal polypoid tumor count to 23 per mouse, with a tumor number inhibition rate of 38% at 0.5 mg/kg.
Reduced average intestinal polypoid tumor count to 15 per mouse, with a tumor number inhibition rate of 58% at 2.5 mg/kg.
Most efficiently inhibited tumor growth across all diameter categories (<2 mm, 2-4 mm, >4 mm) at 2.5 mg/kg.
Chemical Information
-
CAS No. 139307-94-1
-
Molecular Weight 523.18
-
Formula C10H16N5O14P3
-
SMILES
O[C@H]1C[C@H](N2C(N=C(N)NC3=O)=C3N=C2O)O[C@@H]1COP(OP(OP(O)(O)=O)(O)=O)(O)=O
-
Synonyms
8-Oxo-Deoxyguanosine triphosphate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[1]. Sakai Y, et al. A molecular basis for the selective recognition of 2-hydroxy-dATP and 8-oxo-dGTP by human MTH1. J Biol Chem. 2002;277(10):8579-8587. [Content Brief]
[3]. Tsutsui H, et al. 8-oxo-dGTPase, which prevents oxidative stress-induced DNA damage, increases in the mitochondria from failing hearts. Circulation. 2001;104(24):2883-2885. [Content Brief]
[4]. Li J, et al. 8-oxo-dGTP curbs tumor development via S phase arrest and AIF-mediated apoptosis. Free Radic Biol Med. 2023;196:53-64. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)